ImmunityBio is a biotechnology company developing immunotherapies aimed at stimulating immune responses to combat cancer and infectious diseases. The company uses multiple technology platforms, including cytokine fusion proteins, DNA vectors, vaccine vectors, and cell-based approaches, to create therapeutic candidates being advanced into clinical testing for both blood-based and solid tumors. Its approved product Anktiva is used alongside BCG for treating a specific type of bladder cancer, and the company also develops TLR7/8 agonists and maintains partnerships with various research and healthcare organizations.

entry readiness 6 · NOT READY · exit proximity 0

Value area 7.06–8.24 · 12% of 120d volume overhead · clean runway